Key clinical point: Brentuximab vedotin (Bv), given before and after standard chemotherapy, improved survival in untreated Hodgkin lymphoma.
Major finding: Two-year PFS was 84% for patients treated additionally with Bv, compared with 50% historically for standard therapy.
Study details: A prospective phase 2 study involving 48 elderly patients with Hodgkin lymphoma.
Disclosures: Seattle Genetics supported the investigator-initiated trial. Dr. Evens reported consulting or advisory relationships with Seattle Genetics and several other companies.
Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.